PDS Biotechnology Corp — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PDS Biotech announced initial closing of a $22.3M PIPE financing led by Nant Capital LLC (Dr. Soon-Shiong), with a contingent milestone closing tied to PDS0301 Phase 3 FDA submission. NantWorks received a one-year exclusive option to license PDS0101. Cash declined from $26.7M (Dec 2025) to $15.2M (Sept 2026); Q3 net loss was $7.6M ($0.11/share). The company appointed Soon-Shiong and three pharma veterans to the board.
Why this rating
PIPE represents 37% of market cap, materially extends runway but high dilution risk. Prestigious backer and board additions validate science, but accelerating burn and loss of PDS0101 control are concerning.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-4.3% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.98 ▲ 3.42% | at our read · unknown $0.95 | +10 min · unknown $0.93 ▼ 1.68% | +30 min · unknown $0.92 ▼ 3.16% | +1 hr · unknown $0.95 ▲ 0.42% | +4 hrs · unknown $0.82 ▼ 13.58% |
The stock had already moved -3.31% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.